Payment overview · 2025
General Payments
$1,742.08
102 reported records · 21 companies
Healthcare provider profile · identity verified
Christopher Samuel Sewell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JAMESTOWN, TN · NPI 1881699981
Verified facts
What the public records show
CMS Open Payments records show Christopher Samuel Sewell, M.D. received $1,742.08 in general payments during 2025 across 102 reported records.
Novo Nordisk Inc accounted for 11.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.97 | 11.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $182.63 | 10.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.60 | 10.5% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $151.91 | 8.7% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.03 | 8.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.20 | 6.8% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $106.45 | 6.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.91 | 5.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.25 | 5.4% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.68 | 4.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.98 | 4.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.94 | 3.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.43 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.22 | 2.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.61 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.65 | 1.9% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.26 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.25 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.89 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.69 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.53 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,742.08 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $166.04 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.04 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.03 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.57 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $129.66 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $129.66 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.43 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.44 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $106.45 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.91 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $94.25 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.55 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $76.68 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.98 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $67.40 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.17 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.94 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.94 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.68 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.65 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 513 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 146 |
| Omeprazole | Omeprazole | 429 | 137 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 427 | 129 |
| Losartan Potassium | Losartan Potassium | 352 | 98 |
| Furosemide | Furosemide | 301 | 86 |
| Lisinopril | Lisinopril | 280 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 79 |
| Gabapentin | Gabapentin | 242 | 65 |
| Sertraline Hcl | Sertraline Hcl | 238 | 69 |
| Metformin Hcl Er | Metformin Hcl | 234 | 73 |
| Potassium Chloride | Potassium Chloride | 229 | 60 |
| Eliquis | Apixaban | 217 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 65 |
| Jardiance | Empagliflozin | 197 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 50 |
| Meloxicam | Meloxicam | 184 | 65 |
| Prednisone | Prednisone | 184 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 78 |
| Montelukast Sodium | Montelukast Sodium | 161 | 42 |
| Buspirone Hcl | Buspirone Hcl | 160 | 39 |
| Ezetimibe | Ezetimibe | 151 | 56 |
| Allopurinol | Allopurinol | 149 | 35 |
| Methylprednisolone | Methylprednisolone | 146 | 107 |
| Donepezil Hcl | Donepezil Hcl | 135 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 59 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 132 | 33 |
| Azithromycin | Azithromycin | 129 | 106 |
| Trazodone Hcl | Trazodone Hcl | 126 | 41 |
| Simvastatin | Simvastatin | 124 | 35 |
| Famotidine | Famotidine | 123 | 47 |
| Carvedilol | Carvedilol | 117 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 35 |
| Glimepiride | Glimepiride | 109 | 28 |
| Celecoxib | Celecoxib | 106 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 32 |
| Ozempic | Semaglutide | 96 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 25 |
| Farxiga | Dapagliflozin Propanediol | 79 | 21 |
| Xarelto | Rivaroxaban | 77 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 24 |
| Warfarin Sodium | Warfarin Sodium | 72 | suppressed |
| Alprazolam | Alprazolam | 68 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 20 |
| Fluconazole | Fluconazole | 66 | 34 |
| Metformin Hcl | Metformin Hcl | 66 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 11 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Estradiol | Estradiol | 64 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 14 |
| Mupirocin | Mupirocin | 62 | 50 |
| Cefuroxime | Cefuroxime Axetil | 61 | 52 |
| Nitroglycerin | Nitroglycerin | 60 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 57 | 13 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 13 |
| Memantine Hcl | Memantine Hcl | 54 | 15 |
| Spironolactone | Spironolactone | 54 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 40 |
| Levetiracetam | Levetiracetam | 50 | 13 |
| Tramadol Hcl | Tramadol Hcl | 48 | 16 |
| Nystatin | Nystatin | 47 | 36 |
| Cephalexin | Cephalexin | 46 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 33 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 16 |
| Linzess | Linaclotide | 42 | 11 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Repatha Sureclick | Evolocumab | 42 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Atenolol | Atenolol | 39 | 11 |
| Propranolol Hcl | Propranolol Hcl | 39 | 11 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Ibuprofen | Ibuprofen | 32 | 17 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 13 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Naproxen | Naproxen | 24 | 14 |
| Ramipril | Ramipril | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Epinephrine | Epinephrine | 22 | 14 |
| Promethazine Hcl | Promethazine Hcl | 22 | 11 |
| Zonisamide | Zonisamide | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 14 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Entresto | Sacubitril/Valsartan | 17 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,742.08 · 102 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, Wegovy, XHANCE, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error